CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zivo Bioscience Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zivo Bioscience Inc
21 E. Long Lake Road, Suite 100
Phone: (248) 452-9866p:248 452-9866 BLOOMFIELD HILLS, MI  48304  United States Ticker: HEPI HEPI
On April 13, 2022, the management and the audit committee of the board of directors of Zivo Bioscience, Inc. determined that the Company’s unaudited condensed consolidated financial statements for the three and nine month periods ended September 30, 2021, should no longer be relied upon due to an error in accounting treatment for the Company’s License Co-Development Participation Agreements.
Business Summary
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Office, Director John B.Payne 75 1/7/2022 7/19/2013
Chief Financial Officer Keith R.Marchiando 61 1/1/2021 1/1/2021
Independent Director Alison A.Cornell 61 2/8/2021 2/8/2021
Independent Director Christopher D.Maggiore 57 1/1/2017 8/28/2013
Independent Director Nola E.Masterson 76 1/1/2017 9/17/2014

Business Names
Business Name
Health Enhancement Corporation
Health Enhancement Products, Inc.
HEPI
10 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 12/31/2023)
Outstanding Shares: 2,777,639 (As of 3/12/2024)
Shareholders: 209
Stock Exchange: OTC
Federal Tax Id: 870699977


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024